RGFP966 Suppresses Tumor Growth and Migration Through Inhibition of EGFR Expression in Hepatocellular Carcinoma Cells in vitro

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• AnsteeQM, ReevesHL, KotsilitiE, GovaereO, HeikenwalderM. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428. doi:10.1038/s41575-019-0145-731028350
   PubMed Web of Science ®Google Scholar
• KudoM. Lenvatinib in advanced hepatocellular carcinoma. Liver Cancer. 2017;6(4):253–263. doi:10.1159/00047957329234629
   PubMed Web of Science ®Google Scholar
• BruixJ, QinS, MerleP, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-927932229
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGK, MeyerT, ChengAL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa171700229972759
   PubMed Web of Science ®Google Scholar
• LuYS, KashidaY, KulpSK, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 2007;46(4):1119–1130. doi:10.1002/hep.2180417654699
   PubMed Web of Science ®Google Scholar
• LiuJ, LiG, WangX, et al. Droxinostat, a histone deacetylase inhibitor, induces apoptosis in hepatocellular carcinoma cell lines via activation of the mitochondrial pathway and downregulation of FLIP. Transl Oncol. 2016;9(1):70–78. doi:10.1016/j.tranon.2016.01.00426947884
   PubMed Web of Science ®Google Scholar
• LachenmayerA, ToffaninS, CabellosL, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56(6):1343–1350. doi:10.1016/j.jhep.2012.01.00922322234
   PubMed Web of Science ®Google Scholar
• YangWM, YaoYL, SunJM, DavieJR, SetoE. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem. 1997;272(44):28001–28007. doi:10.1074/jbc.272.44.280019346952
   PubMed Web of Science ®Google Scholar
• YanY, AnJ, YangY, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10(4):e8478. doi:10.15252/emmm.20170847829523594
   PubMed Web of Science ®Google Scholar
• McLeodAB, SticeJP, WardellSE, AlleyHM, ChangCY, McDonnellDP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. Prostate. 2018;78(4):266–277. doi:10.1002/pros.2346729243324
   PubMed Web of Science ®Google Scholar
• WellsCE, BhaskaraS, StengelKR, et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One. 2013;8(7):e68915. doi:10.1371/journal.pone.006891523894374
   PubMed Web of Science ®Google Scholar
• HeP, LiK, LiSB, et al. Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer. Int J Oncol. 2018;52(4):1305–1316. doi:10.3892/ijo.2018.428429484387
   PubMed Web of Science ®Google Scholar
• BhaskaraS, KnutsonSK, JiangG, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18(5):436–447. doi:10.1016/j.ccr.2010.10.02221075309
   PubMed Web of Science ®Google Scholar
• LuXF, CaoXY, ZhuYJ, et al. Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway. Cell Death Dis. 2018;9(3):398. doi:10.1038/s41419-018-0428-x29540666
   PubMed Web of Science ®Google Scholar
• LiuC, LiuL, ShanJ, et al. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Lett. 2013;339(1):60–69. doi:10.1016/j.canlet.2013.07.02223879963
   PubMed Web of Science ®Google Scholar
• WuLM, YangZ, ZhouL, et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 2010;5(12):e14460. doi:10.1371/journal.pone.001446021206745
   PubMed Web of Science ®Google Scholar
• LogueJS, MorrisonDK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26(7):641–650. doi:10.1101/gad.186965.11222474259
   PubMed Web of Science ®Google Scholar
• KannangaiR, SahinF, TorbensonMS. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 2006;19(11):1456–1461. doi:10.1038/modpathol.380066516936701
   PubMed Web of Science ®Google Scholar
• ZhouY, WangQ, YangQ, et al. Histone deacetylase 3 inhibitor suppresses hepatitis C virus replication by regulating Apo-A1 and LEAP-1 expression. Virol Sin. 2018;33(5):418–428. doi:10.1007/s12250-018-0057-730328580
   PubMed Web of Science ®Google Scholar
• XuY, XuH, LiM, et al. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Lett. 2019;454:78–89. doi:10.1016/j.canlet.2019.03.04930980868
   PubMed Web of Science ®Google Scholar
• EzzoukhryZ, LouandreC, TrecherelE, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. ‎int J Cancer. 2012;131(12):2961–2969. doi:10.1002/ijc.2760422514082
   PubMed Web of Science ®Google Scholar
• ChouCW, WuMS, HuangWC, ChenCC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One. 2011;6(3):e18087. doi:10.1371/journal.pone.001808721464950
   PubMed Web of Science ®Google Scholar
• KimH, KimY, GohH, JeoungD. Histone deacetylase-3/CAGE axis targets EGFR signaling and regulates the response to anti-cancer drugs. Mol Cells. 2016;39(3):229–241. doi: 10.14348/molcells.2016.224426883907
   PubMed Web of Science ®Google Scholar
• GilbertRE, HuangQ, ThaiK, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int. 2011;79(12):1312–1321. doi:10.1038/ki.2011.3921389970
   PubMed Web of Science ®Google Scholar
• KaragianniP, WongJ. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007;26(37):5439–5449. doi:10.1038/sj.onc.121061217694085
   PubMed Web of Science ®Google Scholar
• KnutsonSK, ChylaBJ, AmannJM, BhaskaraS, HuppertSS, HiebertSW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27(7):1017–1028. doi:10.1038/emboj.2008.5118354499
   PubMed Web of Science ®Google Scholar